Pulmonary complications of targeted therapy
-Immune ...

Pulmonary complications of targeted therapy
-Immune checkpoint inhibitors (e.g. pembrolizumab)
-Pneumonitis is uncommon (~5% of patients) but can be severe.
-It’s a diagnosis of exclusion: rule out infection and malignancy-associated pnuemonitis, as well as radiation pneumonitis.
-Can occur at any time during therapy.
-1/3 of patients are asymptomatic, and the most common presenting symptom is cough
-Imaging characteristics vary widely. There are case reports of pleural effusion associated with a clinical diagnosis pneumonitis, but it’s unclear if this is a drug side effect or a “reactive” response to cancer cell death in response to therapy.

#Clinical #Diagnosis #Radiology #Honc #CheckpointInhibitors #PulmonaryComplications #Patterns
Contributed by

Dr. Gerald Diaz
Board Certified Internal Medicine Hospitalist, GrepMed Editor in Chief 🇵🇭 🇺🇸 - Sign up for an account to like, bookmark and upload images to contribute to our community platform. Follow us on IG:  https://www.instagram.com/grepmed/ | Twitter: https://twitter.com/grepmeded/
Medical jobs
view all


Related content